List of Tables
Table 1. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2021–2026
Table 18. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2027–2032
Table 20. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 27. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 28. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 32. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 33. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 42. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2021–2026)
Table 51. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Type (2027–2032)
Table 52. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2021–2026)
Table 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2027–2032)
Table 60. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2021–2026)
Table 61. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units) by Application (2027–2032)
Table 62. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2021–2026)
Table 69. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2027–2032)
Table 70. Roche Company Information
Table 71. Roche Description and Business Overview
Table 72. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 74. Roche Recent Developments/Updates
Table 75. Novartis Company Information
Table 76. Novartis Description and Business Overview
Table 77. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Novartis Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 79. Novartis Recent Developments/Updates
Table 80. Coherus BioSciences Company Information
Table 81. Coherus BioSciences Description and Business Overview
Table 82. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Coherus BioSciences Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Product
Table 84. Coherus BioSciences Recent Developments/Updates
Table 85. Key Raw Materials Lists
Table 86. Raw Materials Key Suppliers Lists
Table 87. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Distributors List
Table 88. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Customers List
Table 89. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Trends
Table 90. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Drivers
Table 91. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Challenges
Table 92. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Restraints
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
Table 96. Authors List of This Report
List of Figures
Figure 1. Product Picture of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs
Figure 2. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Faricimab Product Picture
Figure 5. Brolucizumab Product Picture
Figure 6. Brolucizumab Product Picture
Figure 7. Other Product Picture
Figure 8. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 10. Age-related Macular Degeneration
Figure 11. Diabetic Retinopathy
Figure 12. Other
Figure 13. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 15. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales (K Units), 2021–2032
Figure 16. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Average Price (US$/Unit), 2021–2032
Figure 17. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 18. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 19. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 20. Top 5 and Top 10 Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Monoclonal Antibody Anti-VEGF Ophthalmic Drugs in 2025
Figure 21. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 22. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 23. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 24. North America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 25. United States Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Canada Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 28. Europe Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 29. Germany Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. France Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. U.K. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Italy Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Russia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 35. Asia Pacific Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 36. China Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. Japan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. South Korea Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. India Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Australia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. China Taiwan Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Southeast Asia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 44. Latin America Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 45. Mexico Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Brazil Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Argentina Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Colombia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 50. Middle East and Africa Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 51. Turkey Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Saudi Arabia Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. UAE Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 55. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 56. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Type (2021–2032)
Figure 57. Global Sales Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 58. Global Revenue Market Share of Monoclonal Antibody Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 59. Global Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Price (US$/Unit) by Application (2021–2032)
Figure 60. Monoclonal Antibody Anti-VEGF Ophthalmic Drugs Value Chain
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
